<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01365390</url>
  </required_header>
  <id_info>
    <org_study_id>115356</org_study_id>
    <nct_id>NCT01365390</nct_id>
  </id_info>
  <brief_title>To Evaluate the Incidence of Acute Otitis Media in Children in Five East European Countries</brief_title>
  <official_title>To Evaluate Incidence of Acute Otitis Media in Children Aged &lt; 6 Years in Five East European Countries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The aim of this study is to provide baseline acute otitis media data in East European
      countries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each subject's involvement in this study will include a retrospective and prospective part.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of acute otitis media in subjects aged &lt; 6 years as diagnosed by a family physician and documented in medical records - retrospective part of the study</measure>
    <time_frame>Retrospective data for 12 months prior to study entry for subjects aged &gt; 1 year or for the entire period since birth for subjects aged &lt; 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of acute otitis media in subjects aged &lt; 6 years as diagnosed by the physician or specialist - prospective part of the study</measure>
    <time_frame>Prospective data for 12 months after study entry</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of otitis media with effusion among acute otitis media cases aged &lt; 6 years in the four consecutive seasons of the year</measure>
    <time_frame>Prospective data for 12 months after study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of suspected acute otitis media as reported by the parent(s)/ legally acceptable representative(s) (and not diagnosed by any physician) during the bi-monthly follow-up</measure>
    <time_frame>Prospective data for 12 months after study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of recurrent acute otitis media</measure>
    <time_frame>Retrospective data for 12 months prior to study entry for subjects aged &gt; 1 year or for the entire period since birth for subjects aged &lt; 1 year and prospective data for 12 months after study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of acute otitis media treatment failures</measure>
    <time_frame>Prospective data for 12 months after study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the impact of acute otitis media on the quality of life of the subject and family by the parental quality of life questionnaire and the Otitis Media-6 children's quality of life questionnaire</measure>
    <time_frame>Prospective data for 12 months after study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct medical, direct non-medical costs and indirect medical costs of one incident of acute otitis media</measure>
    <time_frame>Prospective data for 12 months after study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of acute otitis media as diagnosed by the study physician or any other doctor</measure>
    <time_frame>Prospective data for 12 months after study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of antimicrobial therapy and other forms of treatment for acute otitis media, diagnostic procedures</measure>
    <time_frame>Prospective data for 12 months after study entry</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2258</enrollment>
  <condition>Infections, Streptococcal</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <description>Subjects aged &lt; 6 years who are registered in primary care clinics of any of the participating countries (Estonia, Lithuania, Poland, Romania and Slovenia).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection (Retrospective)</intervention_name>
    <description>For the retrospective part of the study, the parent(s)/ legally acceptable representative(s) of the subjects will be interviewed to collect information on factors potentially related to risk for middle ear diseases. The medical records of the subjects will also be reviewed and all acute otitis media related problems that occurred during the last year prior to enrolment (for subjects aged 1 to &lt; 6 years) or since birth (for subjects aged &lt; 1 year) will be recorded in the electronic case report form.</description>
    <arm_group_label>Cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection (Prospective)</intervention_name>
    <description>For the prospective part of the study, the enrolled subjects will be followed up for a period of 1 year starting from the consent date, during which the parent(s)/ legally acceptable representative(s) will be asked to bring the subject for a visit each time they notice symptoms of acute otitis media or respiratory tract infection in the subject. In case AOM is diagnosed by the investigator, detailed information on the signs, symptoms, severity, course and treatment will be recorded. The parent(s)/ legally acceptable representative(s) of the subjects will also be required to fill up a parental quality of life questionnaire and an Otitis Media-6 children's quality of life questionnaire.</description>
    <arm_group_label>Cohort A</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects aged &lt; 6 years who are registered in primary care clinics of any of the
        participating countries (Estonia, Lithuania, Poland, Romania and Slovenia) will be enrolled
        in this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that parent(s)/ legally acceptable
             representative(s) can and will comply with the requirements of the protocol.

          -  A male or female subject aged &lt; 6 years at the time of enrolment.

          -  The investigator has access to the medical records that contain the medical history of
             the subjects for one year prior to enrolment (for subjects aged 1 to &lt; 6 years) or
             from birth (for subjects aged &lt; 1 year).

          -  Written informed consent obtained from either both parents/ LARs or from one parent/
             LAR of the subject with the declaration of cooperation for one year after enrolment.

        Exclusion Criteria:

          -  Acute otitis media episode at the time of enrolment.

          -  Upper respiratory tract infection at the time of enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10621</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-03147</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-04318</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-07156</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Debica</city>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-018</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kielce</city>
        <zip>25-711</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leczna</city>
        <zip>21-010</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Siemianowice Slaskie</city>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-809</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wejherowo</city>
        <zip>84-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wola</city>
        <zip>43-225</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bacau</city>
        <zip>600316</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brasov</city>
        <zip>500260</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>051821</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Craiova</city>
        <zip>200128</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galati</city>
        <zip>800394</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ljubljana</city>
        <zip>1210</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maribor</city>
        <zip>2000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maribor</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ptuj</city>
        <zip>2250</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ru≈°e</city>
        <zip>2342</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2011</study_first_submitted>
  <study_first_submitted_qc>June 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2011</study_first_posted>
  <last_update_submitted>July 24, 2014</last_update_submitted>
  <last_update_submitted_qc>July 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prospective</keyword>
  <keyword>Incidence</keyword>
  <keyword>otitis</keyword>
  <keyword>observational</keyword>
  <keyword>Epidemiological</keyword>
  <keyword>retrospective</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
    <mesh_term>Streptococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

